Get started

Trend Lines

MTNL's Comeback Story: Innovation and GrowthRevitalizing MTNL: A Bright Future Ahead Target: ₹200 Time frame: 3 years Mahanagar Telephone Nigam Limited (MTNL), a Public Sector Undertaking (PSU), has faced significant challenges in recent years, leading to a decline in its business fortunes. However, despite being knocked out of the competitive telecom market, the company is poised for a resurgence. Embracing New Frontiers As the telecom landscape evolves, MTNL is gearing up to tap into emerging opportunities. The future holds immense promise, and the company is strategically repositioning itself to capitalize on newer forms of communication and technology. 5G: The Game-Changer A key catalyst for MTNL's revival is the ongoing testing of 5G technology. With its potential to enable faster data speeds, lower latency, and greater connectivity, 5G is expected to revolutionize the telecom sector. MTNL's foray into 5G will enable it to offer cutting-edge services, bolstering its competitive edge. Ambitious Targets Three-Year Roadmap Over the next three years, MTNL will concentrate on: Enhancing its 5G capabilities to deliver high-speed, reliable connectivity Developing innovative services and solutions to cater to emerging customer needs Strengthening its network infrastructure to support growing demand Fostering strategic partnerships to drive growth and expansion With a clear vision and robust strategy in place, MTNL is poised to reclaim its position as a leading player in the Indian telecom sector. The future indeed looks bright for this PSU, as it embarks on a transformative journey to reclaim its glory.
NSE:MTNLLong
by liondewarangal
2
PPLPHARMA: 8 Month Slopping Downwards Trendline BreakoutNSE:PPLPHARMA : This Pharma Stock Broke Out of Its Descending Triangle Prison Price Action: - Current Price: ₹216.22 (as of July 15, 2025) - 52-week Range: ₹181.73 - ₹307.90 - The stock has been in a clear descending triangle pattern since November 2024 - Price has been consistently making lower highs while finding support around the ₹190-200 zone - Recent price action shows signs of consolidation near the apex of the triangle Volume Spread Analysis: - Average daily volume: 4.68M shares - Volume spikes were observed during significant price movements in November 2024 and March 2025 - Recent volume has been relatively subdued, indicating a lack of conviction in either direction - Volume pattern suggests an accumulation phase with periodic distribution Key Technical Levels: Support Levels: - Primary Support: ₹190-200 (multiple tests, strong base) - Secondary Support: ₹181.73 (52-week low) - Psychological Support: ₹175-180 zone Resistance Levels: - Immediate Resistance: ₹230-240 (descending trendline) - Secondary Resistance: ₹250-260 (previous swing high) - Major Resistance: ₹280-290 (November 2024 high) Base Formation: - The stock has formed a solid base between ₹190-220 over the past 4 months - This base represents a potential accumulation zone for institutional investors - The horizontal support at ₹200 has been tested multiple times, showing its significance Technical Patterns: - Primary Pattern: Descending Triangle - Secondary Pattern: Potential Cup and Handle formation if the stock breaks above ₹240 - The descending triangle spans approximately 8 months, making it a significant pattern Trade Setup: Entry Strategy: - Breakout Entry: Buy above ₹240 with volume confirmation - Support Entry: Buy near ₹200-205 for swing trade - Conservative Entry: Wait for weekly close above ₹245 for momentum play Exit Levels: - Short-term Target: ₹260-270 - Medium-term Target: ₹290-300 - Long-term Target: ₹350-380 Stop-Loss Levels: - For breakout trades: ₹225 (below breakdown level) - For support trades: ₹185 (below 52-week low) - Trailing stop: 8-10% below entry price Position Sizing: - Risk per trade: Maximum 2% of portfolio - For ₹240 entry with ₹225 stop: Position size = (Portfolio × 0.02) / 15 - Suggested allocation: 1-2% of total portfolio for this trade Risk Management: - Maximum holding period: 3-6 months - Review position if stock fails to break ₹240 within 4 weeks - Partial profit booking at ₹270 (book 50% position) - Trail stop-loss after first target achievement Sectoral and Fundamental Backdrop: Sectoral Analysis: - The India Pharmaceutical Market size is estimated at USD 66.66 billion in 2025, and is expected to reach USD 88.86 billion by 2030, at a CAGR of 5.92% during the forecast period (2025-2030) - India's pharmaceutical industry ranks third globally in pharmaceutical production by volume and 14th by value, supported by a well-established domestic sector comprising approximately 3,000 drug companies and over 10,000 custom manufacturing units - The Indian pharmaceuticals industry is expected to grow 9-11% in the financial year 2024, as per ICRA - The biosimilars market in India is expected to grow at a CAGR of 22%, reaching USD 12 billion by 2025, representing nearly 20% of the country's pharmaceutical market Company Fundamentals: - Market Cap: 28,745 Crore (up 42.2% in 1 year), Revenue: 9,151 Cr, Profit: 91.1 Cr - Stock is trading at 3.53 times its book value - The company has a low interest coverage ratio, Promoter Holding: 34.94% - The P/E ratio of Piramal Pharma Ltd is 324 times as on 15-July-2025, a 651% premium to its peers' median range of 33.45 times Business Overview: - The company has a 49% ownership interest in a joint venture with Allergan India Pvt. Ltd (Avvyie, a US pharmaceutical company, holds a 51% ownership interest), which is one of the leading pharmaceutical companies in Ophthalmology formulations in India - Strong presence in glaucoma and dry eye treatments - Diversified portfolio across multiple therapeutic areas Analyst Targets: - Recent research reports show an average share price target of 253 - The estimated share price target for 2025 can range from ₹198 to ₹350 Investment Thesis: Bullish Factors: - Strong sectoral tailwinds with the Indian pharma market growing at 5.92% CAGR - Solid base formation indicating institutional accumulation - Reasonable valuation compared to growth prospects - Strategic partnership with Allergan provides a competitive advantage Risk Factors: - A high P/E ratio indicates expensive valuation - A low interest coverage ratio suggests financial stress - Regulatory changes in the pharmaceutical sector My Take: NSE:PPLPHARMA presents a mixed technical picture with a descending triangle pattern Breakout but strong support base. The stock is at a crucial juncture where a breakout above ₹240 could lead to significant upside, while a breakdown below ₹190 would confirm further weakness. Given the positive sectoral outlook and the company's strategic positioning, a breakout trade above ₹240 with proper risk management offers favorable risk-reward ratio. Keep in the Watchlist. NO RECO. For Buy/Sell. 📌Thank you for exploring my idea! I hope you found it valuable. 🙏FOLLOW for more 👍BOOST if you found it useful. ✍️COMMENT below with your views. Meanwhile, check out my other stock ideas on the right side until this trade is activated. I would love your feedback. Disclaimer: "I am not a SEBI REGISTERED RESEARCH ANALYST AND INVESTMENT ADVISER." This analysis is intended solely for informational and educational purposes and should not be interpreted as financial advice. It is advisable to consult a qualified financial advisor or conduct thorough research before making investment decisions.
NSE:PPLPHARMALong
by Karanshah137
19
renderwithme | ETH Price Prediction for next six Months 2025 Price Prediction for next six Months 2025 Price Range: Based on various forecasts, Ethereum (ETH) is expected to trade between approximately $2,500 and $3,360 in August 2025. The minimum price could be around $2,519.80, with a potential peak of $3,360.36. The average trading price is projected to be around $2,800–$3,100. Bullish Scenario: If bullish momentum continues, driven by factors like institutional inflows or positive network developments, ETH could test the $3,150–$3,300 range or even approach $3,500 by late August. A breakout and close above $3,100 could trigger a rally toward $3,550–$3,800. Bearish Scenario: If market sentiment turns negative, due to macroeconomic uncertainties or regulatory pressures, ETH could dip to $2,470–$2,500, with a potential further decline to $2,400 if support levels fail. ~~ Disclaimer ~~ This analysis is based on recent technical data and market sentiment from web sources. It is for informational \ educational purposes only and not financial advice. Trading involves high risks, and past performance does not guarantee future results. Always conduct your own research or consult a SEBI-registered advisor before trading. # Boost and comment will be highly appreciated.
BINANCE:ETHUSDLong
by renderwithme
4
$EXK ready to explode and tear it's multi year resistance NYSE:EXK chart is special, this is a setup which has my high conviction. Their Terronera project should be ready to ramp up this month, and it will also bring their costs AISC down, This will double their production to almost 15 million Aq. Eq ounces + Kolpa Project 5 million Ag eq., which they just acquired, will make them a 20 million Ag eq producer. As silver moves up their OPM% will keep inching up higher. And the volume buildup is screaming a thumping buy.
NYSE:EXKLong
by nishant_bhatt
EURUSD: are the bulls taking control?EURUSD is currently trading around 1.1691 and maintaining a bullish structure with consistently higher lows. On the H4 chart, a symmetrical triangle is forming, and price may break out toward the 1.1823 target if it can overcome the resistance trendline. On the news front, the US dollar has weakened as the Fed has yet to provide a clear signal on rate cuts. Meanwhile, Eurozone economic sentiment is improving, supported by a slight uptick in manufacturing and services data. This reinforces the euro's recovery and keeps upward pressure on EURUSD. If the 1.1660 support zone holds firm, the upcoming breakout could trigger a strong bullish move. Buyers are waiting for confirmation — are you in the game?
Long
by Rocky_trade_
5
MUHIBAH - Downward slopping INVERTED HEAD & SHOULDERSMUHIBAH - CURRENT PRICE : RM0.630 On 11 July 2025 the stock made a small gap up and closed above minor down trendline. Eventhough it closed as a doji candle, it is viewed as BULLISH as the price broke out inverted head and shoulders NECKLINE RESISTANCE with high trading volume. There is a higher low recently which is usually occurs in this chart pattern - indicating possible bottom have reached. Nearest target will be RM0.680 and RM0.720 while support will be RM0.595. Take note that the first target of RM0.680 also approximately near the major down trendline. ENTRY PRICE : RM0.625 - RM0.630 TARGET : RM0.680 (+7.94%) and RM0.720 (+14.29%) SUPPORT : RM0.595 (-5.56%)
MYX:MUHIBAHLong
by IMRAN_96
Eternal Resumes Bullish Trend After First Major Correction, EyesTopic Statement: Eternal has bounced back strongly from its first major correction, finding solid support at key levels and now rising toward a potential breakout. Key Points: * The stock respects a clear trend line, consistently receiving support along it * Price retraced to the 38.2% Fibonacci level around 200, where it found strong buying interest and reversed * As it rises toward 300, the stock is set to form a triple top, and a breakout above this level could lead to a new higher high
NSE:ETERNAL
by yogeshwar
1